Trial reportPharmacogenomics
Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial.
Trial report in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05667766 (Minimising Adverse Drug Reactions and Verifying Economic Legitimacy - Pharmacogenomics Implementation in Children), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy - Pharmacogenomics Implementation in Children (MARVEL-PIC)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacogenomic (PGx) testing can optimize drug efficacy and minimize toxicity, but prescriber adherence to PGx recommendations remains unclear. We aimed to quantify clinician adherence to international PGx recommendations in a cohort of pediatric oncology patients.
methodsWe reviewed files of children with PGx recommendations generated through the MARVEL-PIC (NCT05667766) trial. Patients were included if ≥12 weeks had passed since their PGx report was released to clinicians. Prescribing events were identified for actionable and relevant PGx recommendations and classified as "explicitly followed," "inadvertently followed," or "not followed." Adherence was assessed by patient, drug, and recommendation.
results2,063 PGx recommendations were available for 216 patients. Sixty‑four (3.1%) recommendations were actionable and relevant to 44 patients and 10 drugs within the 12-week study period. Recommendations were explicitly followed in 57/288 (19.8%) events, inadvertently followed in 145 (50.3%) events, and not followed in 86 (29.9%) prescribing events. Mercaptopurine demonstrated the highest explicit adherence (87.5%). No significant associations were observed between adherence and age group, disease group, drug type, or strength of recommendation.
conclusionAdherence to PGx recommendations was very low, highlighting a need to understand barriers to PGx implementation, increase education of healthcare professionals, and consider clinical decision support tools to facilitate adherence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.